Navigation und Service

Zielgruppeneinstiege

Abstract zur Publikation: Surveillance of Transmitted HIV Drug Resistance Across Europe in the Era of Newly Approved Antiretroviral Drugs

Bartmeyer B, Kücherer C (2009): Surveillance of Transmitted HIV Drug Resistance Across Europe in the Era of Newly Approved Antiretroviral Drugs.
Eur. Infect. Dis. 3 (1): 31-35.

Over the last few years, the prevalence of transmitted HIV-1 drug resistance (TDR) has not risen in the industrialised countries of western Europe. As recently reported by the European surveillance programme monitoring the spread of HIV resistance (SPREAD), the overall prevalence of TDR in drug-naïve individuals who have been newly diagnosed with HIV is stable at 9%. In most countries, genotypic resistance analysis is routinely performed before antiretroviral treatment initiation and national drug-resistance databases have been established as central repositories for resistance results. Incomplete suppression of viral replication caused by insufficient drug levels, low adherence, compartmentation and individual pharmacogenetic characteristics of the patient are important factors influencing TDR. Since the development of second-generation and new antiretroviral drug classes, treatment options for patients infected with HIV have significantly improved. However, the analysis of resistance pathways to new antiretroviral drugs is key to enhancing the understanding of future risks regarding viral failure and guaranteeing a successful treatment outcome for patients infected with HIV.

Zusatzinformationen

Gesundheitsmonitoring

In­fek­ti­ons­schutz

Forschung

Kom­mis­sio­nen

Ser­vice

Das Robert Koch-Institut ist ein Bundesinstitut im Geschäftsbereich des Bundesministeriums für Gesundheit

© Robert Koch-Institut

Alle Rechte vorbehalten, soweit nicht ausdrücklich anders vermerkt.